Generics, Budgeting, And The Stubborn Persistence Of Cost Savings
Executive Summary
ANDA sponsors want inflation penalty in Medicaid repealed, but long struggle to eliminate IPAB shows just how hard it may be for generics industry to get that 'fix'.
You may also be interested in...
Medicare Part D Drug Price Policies May Offer Financial Trade-Offs
Higher manufacturer discounts required in donut hole under new budget law could offset somewhat by point-of-sale rebates in Part D, which are expected to be included in President Trump's FY 2019 budget proposal.
Aduhelm In Medicaid: States Must Cover, CMS Official Says
Medicaid’s pharmacy director says the Biogen Alzheimer’s drug is ‘currently a covered outpatient drug.’ As the payer of last resort, Medicaid could find itself significantly impacted by a Medicare national coverage decision.
Project Orbis Nears 30 Approvals In Oncology; Could China Be Added?
A review of drugs and supplemental uses since the project’s inception shows roughly one-third of the products reviewed have been NMEs.